As soon as the news broke that Melky Cabrera is signing with the Blue Jays, several people in my Twitter timeline said things to the effect that it must be the case that baseball’s drug testing system is broken if someone fresh off a PED suspension can sign a two-year, $16 million deal. And I get the frustration I suppose, because no one likes to see cheaters prosper, but whatever you think of this deal, it cannot reasonably be interpreted as an indictment of the drug testing system.
Based on his last two seasons, Melky Cabrera was poised to make something like $40 million bucks in free agency. Maybe more. And now, though he is not going to be hurting or anything, he’s going to make less than half that. Say what you want about the drug testing system, but tens of millions of dollars in lost wages is no small penalty.
Now, that doesn’t mean that Cabrera’s use of PEDs didn’t still somehow help him. I’ll acknowledge that $16 million over two years may still be more than he ever could have got if he never took PEDs. But we don’t know. We simply have no way of knowing how much of Cabrera’s improvement over the past two years was a function of PEDs and how much of it was natural improvement as he reached an age when most players put up their best years. Maybe he would have turned into the player his potential always suggested he might, in which case he’d still be making a good living. Maybe he wouldn’t have. If anyone claims to know this for sure, they’re making crap up, because it’s unknowable with current science and baseball analytics.
But no matter what amount of advantage he still realized, it’s on Cabrera, human nature and the incentives any person — and any team like the Blue Jays — is subject to, not baseball’s drug program. Just as no laws, no matter how tough, can eradicate crime, no drug testing program can eradicate cheating. People will still do it from time to time. And when they do, they run the risk of getting caught. And when they get caught, they are punished. As Melky Cabrera was punished, to the tune of tens of millions of dollars.
Still not good enough for you? OK, that’s your right to think so. But know that the only logical conclusion to such thinking is to advocate for a lifetime ban for first time drug users. Because that’s the only thing that would have kept a team from taking a chance on Melky Cabrera like the Blue Jays are. And while you may disagree, I think such a thing would be way too damn harsh.
The news has gone from bad to worse for Dodgers’ left-hander Julio Urias, who is scheduled for anterior capsule surgery on his left shoulder next Tuesday and expected to be sidelined through the middle of the 2018 season. His MRI came back negative on Wednesday, giving the Dodgers some hope that the 20-year-old’s bout of shoulder inflammation wasn’t masking any structural damage, but the pain lingered several days later and prompted further concern from the club. The procedure will be performed by Dr. Neal ElAttrache.
Urias was optioned to Triple-A Oklahoma City in late May and placed on the disabled list with left shoulder discomfort several weeks into his assignment. At the major league level, he owned a 5.40 ERA, 5.4 BB/9 and 4.2 SO/9 through 23 1/3 innings, going 0-2 in five starts with Los Angeles. He made a brief rebound in Triple-A, posting three wins and striking out 17 of 67 batters in 17 1/3 innings before landing on the DL.
It’s a tough blow for the southpaw, who had yet to hit his stride in the majors before getting sidelined with shoulder issues. The Dodgers were especially mindful of this outcome for Urias, and had taken preventative measures to protect his arm by establishing a strict innings limit last season. According to club president Andrew Friedman, there’s a small silver lining here: while Urias’ injury will keep him out of work for at least 12 months, he doesn’t appear to have sustained any damage to his labrum or rotator cuff, and could be facing a much more streamlined recovery process as a result. Whether he’ll be able to rebound once he takes the mound again remains to be seen.
Tigers’ right-handed reliever Francisco Rodriguez was released on Friday, per a team announcement. The club recalled fellow right-hander Bruce Rondon from Triple-A Toledo in a corresponding move.
The former closer got the boot after losing his closing role in early May, giving left-hander Justin Wilson a chance to impress at the back end of the bullpen. It’s been a rough year for Rodriguez, who manufactured six blown saves and a 7.82 ERA, 3.9 BB/9 and 8.2 SO/9 over 25 1/3 innings for the Tigers. The final straw, it seemed, came with Robinson Cano‘s grand slam in the seventh inning of the Tigers’ 6-9 loss to the Mariners on Thursday.
While the demotion to a clean-up role and an apparent lack of communication caused Rodriguez considerable frustration, he’s two years removed from his last dominant performance as a major league closer and has shown few signs of returning to form. His recent slump doesn’t diminish the impressive totals he’s racked up over his 16-year career — 437 saves and six All-Star nominations among them — but if he can’t break out of it soon, he may not receive the kind of high leverage role he’s seeking with another big league team, either.